Thermo Fisher Scientific Inc (TMO): Today's Featured Health Care Winner

Thermo Fisher Scientific ( TMO) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.7%. By the end of trading, Thermo Fisher Scientific rose $1.97 (2.4%) to $85.37 on average volume. Throughout the day, 3,206,947 shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 2,979,100 shares. The stock ranged in a price between $84.00-$85.76 after having opened the day at $84.09 as compared to the previous trading day's close of $83.40. Other companies within the Health Care sector that increased today were: Mela ( MELA), up 17.6%, ZIOPHARM Oncology ( ZIOP), up 16.2%, Cytokinetics ( CYTK), up 11.1% and Intercept Pharmaceuticals ( ICPT), up 9.8%.

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics. Thermo Fisher Scientific has a market cap of $29.8 billion and is part of the health services industry. The company has a P/E ratio of 23.0, above the S&P 500 P/E ratio of 17.7. Shares are up 30.8% year to date as of the close of trading on Wednesday. Currently there are 12 analysts that rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the negative front, Pingtan Marine Enterprise ( PME), down 65.1%, Mast Therapeutics ( MSTX), down 37.2%, Peregrine Pharmaceuticals ( PPHM), down 23.1% and PTC Therapeutics ( PTCT), down 15.1% , were all laggards within the health care sector with Vivus ( VVUS) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Jim Cramer: Agilent Technology Has Been One of My Favorites

Secondaries Get Primary Attention; Discerning Market -- Cramer's Top Thoughts

Cramer: Secondary Offerings Get Primary Attention

The Stock Market Is on Fire, Especially in These Sectors: Market Recon

PerkinElmer Among Targets Fitting Thermo Fisher's M&A Criteria